• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Virta Health Helps AutoZone Employees Reverse Type 2 Diabetes

by Jasmine Pennic 12/01/2022 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Type 2 diabetes reversal leader Virta Health revealed promising one-year outcomes from its partnership with AutoZone, Inc., a retailer and distributor of automotive replacement parts and accessories in the Americas.

– Virta provides virtual, continuous health coaching, medical supervision and personalized nutrition to help patients reverse their metabolic disease, lose weight, + get off medications. At one year, AutoZoners experience long-term blood sugar control and clinically-significant weight loss while eliminating over half of diabetes medications.

AutoZone’s Health Outcomes for Employees

AutoZone currently offers Virta’s type 2 diabetes reversal, prediabetes reversal, type 2 diabetes management, and obesity and weight loss solutions to eligible AutoZoners at no-cost. Over the past twelve months, AutoZoners living with type 2 diabetes, prediabetes, and obesity have achieved transformative results with Virta, including:

– Medication Deprescription: Type 2 diabetes patients eliminated over half of diabetes medications (excluding metformin), including a 73% reduction in insulin prescribed after 12 months.

– Blood Sugar Reduction: Estimated HbA1c (a measure of average blood sugar) improved by 1% on average for diabetes patients. Every one-point decrease in HbA1c reduces the risk of long-term diabetes complications—such as eye, kidney, and nerve disease—by up to 40%.

– Clinically Significant Weight Loss: Across all groups, patients saw at least 8% weight loss on average (5% is the benchmark for FDA-approved weight-loss drugs and what is considered clinically significant). AutoZoners enrolled in Virta’s obesity program experienced 9% weight loss.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: diabetes, Diabetes Management, Diabetes Reversal, FDA, insulin, medication, Obesity, risk, Type 2 Diabetes, Virta Health

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |